BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Trump Buys SpaceX Shares After Record IPO 
Nvidia Options Price in $280 Billion Earnings Swing 
Tesla Raises Cybertruck Prices by $5,000 in US 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Add as a preferred source on Google
ROCKVILLE, Md., April 24, 2018 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2018 after 5:00 p.m. ET on Tuesday, May 8, 2018.
Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to discuss the first quarter 2018 business results on Wednesday, May 9, 2018 at 9:00 a.m. ET. Following management’s prepared discussion and analysis, the call will be open for questions.
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
| Conference dial-in: | (877) 288-1043 | |
| International dial-in: | (970) 315-0267 | |
| Conference ID: | 1568978 | |
| Conference Call Name: | Supernus Pharmaceuticals First Quarter 2018 Earnings Conference Call |
Following the live call, a replay will be available on the Company's website under the 'Investors' section. The webcast will be available on the Company's website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]
